472 filings
Page 9 of 24
6-K
bkmpfgosutk
23 Aug 21
Current report (foreign)
6:14am
6-K
8zun 6mm8c
9 Aug 21
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
6:42am
6-K
4yth2kd
30 Jul 21
Current report (foreign)
6:08am
6-K
74n0magg8c2992fvefg
28 Jul 21
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
8:17am
6-K
z35ew
28 Jul 21
Current report (foreign)
6:42am
6-K
x45wrbo790i
23 Jul 21
Current report (foreign)
8:46am
6-K
upjz55xotdg dpsd67ew
16 Jul 21
Current report (foreign)
6:33am
6-K
a33tk9 hy7
14 Jul 21
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
6:19am
6-K
snr5tfhl9dj77zz2xof
13 Jul 21
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
6:22am
6-K
6fihd7r
12 Jul 21
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering
10:19am
6-K
ohbsp
6 Jul 21
Current report (foreign)
6:24am
6-K
czslbz tjtx3iz07e8b0
2 Jul 21
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
7:14am
6-K
8y3lgrk1g
30 Jun 21
HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong
6:34am
6-K
k6esd
29 Jun 21
Current report (foreign)
6:40am
6-K
jx5o5
24 Jun 21
Current report (foreign)
9:07am
424B5
rwky8991vf4jb19e6w
24 Jun 21
Prospectus supplement for primary offering
8:42am
6-K
w6n y8ysjjnew33u26e1
24 Jun 21
Current report (foreign)
7:33am
6-K
ytz5vl84j1f it63sdv
23 Jun 21
HUTCHMED Announces Pricing of Global Offering
10:33am
6-K
n5jj8a9h70p2
21 Jun 21
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
7:39am
6-K
jqt3990wbzsr4
21 Jun 21
HUTCHMED Launches Hong Kong Initial Public Offering
7:36am